The International Association for the Study of Lung Cancer (IASLC) has published its first version of the Atlas of EGFR Testing in Lung Cancer, which provides up-to-date recommendations on the testing process and interpretation of the results.
The Atlas was initially made available to attendees at the IASLC 18th World Conference on Lung Cancer (WCLC) and was later published in PDF form on the IASLC website.
Epidermal growth factor receptor (EGFR) testing is often used to aid treatment decision-making by determining whether a patient with non-small cell lung cancer may benefit from targeted therapy. By releasing the Atlas, the IASLC is continuing to provide pathologists, clinicians, and other health care professionals with the latest, comprehensive information on EGFR testing topics, including tumor sample optimal practices and quality assurance.
“Because the use of EGFR testing is growing rapidly, this Atlas is a critical tool to ensure best practices worldwide,” commented David Carbone, MD, PhD, and other editors of the guide. “The IASLC is committed to developing and implementing global standards that make it possible for all lung cancer patients, regardless of where they live, to receive the best possible care. This guide empowers health care professionals to utilize EGFR testing to create better outcomes for their patients.”
The Atlas was first made available in a print version in English, but is now available in Japanese and Chinese as well. It will soon be available in print in Portuguese, Spanish, and Korean, as well as on the IASLC WCLC conference mobile app.—Zachary Bessette